HC Wainwright Weighs in on Oculis’ Q1 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Oculis in a research note issued on Monday, May 12th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis’ Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.40) EPS and Q4 2026 earnings at ($0.40) EPS.

Several other research firms have also recently commented on OCS. Robert W. Baird raised their target price on shares of Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research report on Thursday, March 13th. Chardan Capital lifted their price target on shares of Oculis from $28.00 to $33.00 and gave the company a “buy” rating in a research report on Friday, May 9th.

Oculis Trading Down 2.7%

NASDAQ:OCS opened at $17.28 on Tuesday. The company has a 50-day moving average price of $17.96 and a 200-day moving average price of $18.39. Oculis has a 12 month low of $10.79 and a 12 month high of $23.08. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The stock has a market cap of $754.48 million, a price-to-earnings ratio of -8.95 and a beta of 0.27.

Oculis (NASDAQ:OCS) last posted its earnings results on Thursday, May 8th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.26). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. The company had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $0.22 million.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Bellevue Group AG bought a new stake in Oculis during the 4th quarter valued at about $170,000. XTX Topco Ltd bought a new stake in Oculis during the 4th quarter valued at about $225,000. Kestra Private Wealth Services LLC bought a new stake in Oculis during the 1st quarter valued at about $234,000. Geode Capital Management LLC increased its stake in Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after purchasing an additional 1,800 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in Oculis during the 4th quarter valued at about $389,000. 22.30% of the stock is owned by hedge funds and other institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.